Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 1070806

Drug Profile

GSK 1070806

Alternative Names: GSK-1070806

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK
  • Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 18 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • No development reported Crohn's disease; Delayed graft function; Inflammatory bowel diseases
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 15 Nov 2023 Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly, Treatment-experienced) in USA, Canada (SC) (NCT05999799) (EudraCT2023-505414-15-00)
  • 08 Nov 2023 Phase-II clinical trials in Atopic dermatitis (unspecified route), prior to November 2023 (GSK pipeline, November 2023)
  • 24 Aug 2023 GlaxoSmithKline plans a phase II trials for Atopic Dermatitis (In adults, In the elderly, Treatment-experienced) (SC, Injection), in December 2023 (NCT05999799) (EudraCT2023-505414-15-00)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top